- Algernon (AGN) has announced a marketed public offering of units
- Each unit will consist of one Class A common share and one share purchase warrant
- The quantity and pricing of units to be offered have yet to be determined
- The offering is expected to close on or about July 4, 2022
- Algernon is a clinical-stage pharmaceutical development company investigates safe, approved drugs for new disease applications
- Algernon Pharmaceuticals Inc. (AGN) opened trading at $5.65 per share
Algernon (AGN) has announced a marketed public offering of units with Research Capital as the sole agent and sole bookrunner.
The size and pricing of the offering have yet to be determined.
Each unit will consist of one Class A common share and one share purchase warrant. Each warrant will entitle the holder to purchase one additional common share for five years.
The agents will be offered an over-allotment option, and warrants issued under the offering will be subject to an acceleration clause.
The offering is expected to close on or about July 4, 2022.
Net proceeds from the offering will fund research and development programs and working capital purposes.
Algernon is a clinical-stage pharmaceutical development company investigating safe, approved drugs for new disease applications.
Algernon Pharmaceuticals Inc. (AGN) opened trading at $5.65 per share.